1.3Ether at the X position
The core and phenyl group form a core–O–phenyl linkage with two carbon–oxygen single bonds. The oxygen serves as a hydrogen-bond acceptor and provides a bent connection between the two groups.
Generated automatically. Not reviewed by a person. Not legal advice or an opinion.
Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
The core and phenyl group form a core–O–phenyl linkage with two carbon–oxygen single bonds. The oxygen serves as a hydrogen-bond acceptor and provides a bent connection between the two groups.
The nitrogen bonds to the phenyl group through an aromatic carbon and retains its bonds to the core and R2. Conjugation between the nitrogen lone pair and the phenyl ring reduces the lone pair's availability for protonation.
A tetrahydropyran-4-yl group attaches through the ring carbon opposite the oxygen. The chair conformation gives the group a three-dimensional shape, and the ring oxygen serves as a hydrogen-bond acceptor.
Three methylene groups and the bound nitrogen form the saturated ring. The ring holds the two carbon bonds at nitrogen close together and connects to the rest of the molecule through that nitrogen.
The segment connects the same two endpoints through two repeat units joined in series. The second unit adds one repeat unit's worth of bonds to the path between the attachment atoms.
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
A veterinary laboratory uses a small-molecule inhibitor to study granule release in neutrophils isolated from bovine blood. The assay plate contains matched wells for unstimulated cells, stimulated cells with vehicle, and stimulated cells with the inhibitor. An immunoassay measures lactoferrin in the supernatant, and a membrane integrity assay measures cell damage in parallel.
A 96-well plate contains replicate neutrophil cultures exposed to inhibitor concentrations from 0.1 to 30 micromolar for 15 minutes before stimulation. Independent wells supply supernatant at 2, 5, 15, and 30 minutes after stimulation. Each time point includes a stimulated vehicle control and an unstimulated control, and an immunoassay measures released lactoferrin.
A two-channel microfluidic device carries an endothelial monolayer on a porous membrane between the channels. Neutrophils and the inhibitor enter the vascular channel, and a chemoattractant in the opposing channel establishes a gradient across the membrane. Microscopy counts neutrophils that cross the membrane, and immunoassays measure released granule proteins in effluent from both channels.
A perfusion chamber holds a precision-cut lung slice on a porous support and circulates medium containing the inhibitor. Fluorescently labeled neutrophils enter the chamber with the perfusate, and matched chambers receive vehicle with the same inflammatory stimulus. Imaging quantifies neutrophil accumulation in the tissue, and effluent sampling tracks extracellular lactoferrin over time.
A liquid handler dispenses inhibitor dilutions and stimulus into a plate of neutrophils and adds fluorescent antibodies against surface CD63 and CD66b at a fixed time after stimulation. A plate-sampling flow cytometer records antibody fluorescence and a viability dye for each cell. Software selects live single cells, normalizes each marker to the stimulated vehicle control, and fits a separate concentration-response curve for each marker.
R1 is methoxy, —OCH3, with oxygen bonded directly to the core. The group contains one alkyl carbon, and its ether oxygen serves as a hydrogen-bond acceptor.
A 2,2,2-trifluoroethyl group attaches through its methylene carbon as —CH2CF3. Three fluorine atoms occupy the terminal carbon.
A phenyl ring serves as Cy and carries one cyano group at the carbon opposite its attachment point. The nitrile carbon bonds directly to the ring, and the carbon–nitrogen triple bond gives the substituent a linear axis.
R is H and R′ is ethyl, giving —NHCH2CH3. The nitrogen bonds to the parent group, one hydrogen, and the methylene carbon of the ethyl group.
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
C1-6alkylcarbonyloxy; carboxyl; cyano; nitro; amino; mono- or di(C1-6alkyl)amino; polyhaloC1-6alkyl; polyhaloC1-6alkyloxy; polyhaloC1-6alkylthio; R7—C(═O)—; —NHC(═O)H; —C(═O)NHNH2;A · US 2006/0063789 A1 · ¶ 15
and wherein l, n, m, Y, and R6, R7, R8, R9, R10, R11, R12 and R13 are as defined in the following groups (A) to (C): (A) when l is 0-3; n is 0-3; m is 0 or m is 1 and Y is —C(R30)(R31)—; and the sum of l and n is 0-3: (i) R6, R7, R8, R9, R10 and R11 are independently selected from the group consisting of H, alkyl, cycloalkyl, cycloalkylalkyl, aryl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, heterocycloalkylalkyl, alkenyl, alkynyl, halo, —NO2, —CN, —N(R15)(R16),B · US 2009/0312341 A1 · ¶
C2-6alkenyl substituted with one or more halogen atoms or cyano;A · US 2006/0063789 A1 · ¶ 15
and wherein each of the alkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, alkenyl and alkynyl groups in R, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R24, R25 and R30 are independently unsubstituted or substituted by 1 to 5 R32 groups independently selected from the group consisting of halo, alkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkylB · US 2009/0312341 A1 · ¶ 36
and wherein l, n, m, Y, and R6, R7, R8, R9, R10, R11, R12 and R13 are as defined in the following groups (A) to (C): (A) when l is 0-3; n is 0-3; m is 0 or m is 1 and Y is —C(R30)(R31)—; and the sum of l and n is 0-3: (i) R6, R7, R8, R9, R10 and R11 are independently selected from the group consisting of H, alkyl, cycloalkyl, cycloalkylalkyl, aryl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, heterocycloalkylalkyl, alkenyl, alkynyl, halo, —NO2, —CN, —N(R15)(R16),B · US 2009/0312341 A1 · ¶
C1-6alkyl substituted with a monocyclic, bicyclic or tricyclic saturated carbocycle or with a monocyclic, bicyclic or tricyclic partially saturated carbocycle or with a monocyclic, bicyclic or tricyclic aromatic carbocycle or with a monocyclic, bicyclic or tricyclic saturated heterocycle or with a monocyclic, bicyclic or tricyclic partially saturated heterocycle or with a monocyclic, bicyclic or tricyclic aromatic heterocycle; each of said groups representing R8 may optionallA · US 2006/0063789 A1 · ¶ 15
R19 is optionally substituted alkyl, —SO2R18, —C(O)R18 or optionally substituted heteroarylalkyl, preferably alkyl, optionally substituted benzyl, benzoyl, (optionally substituted heteroaryl)alkyl, —SO2alkyl, —SO2(optionally substituted phenyl), —SO2-naphthyl, (phenyl-alkenyl)-SO2—, —SO2— (optionally substituted benzyl), —SO2— (optionally substituted heteroaryl), phenyl, —C(O)alkyl, —C(O)-(phenyl), —C(O)-heteroaryl, —C(O)N(alkyl)2, —C(O)—O-benzyl, —SO2— (optionally substituteB · US 2009/0312341 A1 · ¶
R20 is a monocyclic, bicyclic or tricyclic saturated carbocycle; a monocyclic, bicyclic or tricyclic partially saturated carbocycle; a monocyclic, bicyclic or tricyclic aromatic carbocycle; a monocyclic, bicyclic or tricyclic saturated heterocycle; a monocyclic, bicyclic or tricyclic partially saturated heterocycle; a monocyclic, bicyclic or tricyclic aromatic heterocycle;A · US 2006/0063789 A1 · ¶ 15
“Heterocyclyl” (or heterocycloalkyl) means a non-aromatic saturated monocyclic or multicyclic ring system comprising about 3 to about 10 ring atoms, preferably about 5 to about 10 ring atoms, in which 1-3, preferably 1 or 2 of the atoms in the ring system is an element other than carbon, for example nitrogen, oxygen or sulfur, alone or in combination.B · US 2009/0312341 A1 · ¶ 84
R20 is a monocyclic, bicyclic or tricyclic saturated carbocycle; a monocyclic, bicyclic or tricyclic partially saturated carbocycle; a monocyclic, bicyclic or tricyclic aromatic carbocycle; a monocyclic, bicyclic or tricyclic saturated heterocycle; a monocyclic, bicyclic or tricyclic partially saturated heterocycle; a monocyclic, bicyclic or tricyclic aromatic heterocycle;A · US 2006/0063789 A1 · ¶ 15
and wherein each of the alkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, alkenyl and alkynyl groups in R, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R24, R25 and R30 are independently unsubstituted or substituted by 1 to 5 R32 groups independently selected from the group consisting of halo, alkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkylB · US 2009/0312341 A1 · ¶ 36
Y3 or Y4 each independently are a direct bond, C1-6alkanediyl, C2-6alkenediyl or C2-6alkynediyl; n is 1 or 2; m is 1 or 2; p is 1 or 2; r is 1 to 5; s is 1 to 3; aryl is phenyl or phenyl substituted with one, two, three, four or five substituents each independently selected from halo, C1-6alkyl, C3-7cycloalkyl, C1-6alkyloxy, cyano, nitro, polyhaloC1-6alkyl and polyhaloC1-6alkyloxy; provided that —X—R2 and/or R3 is other than hydrogen; and provided that the following compoundsA · US 2006/0063789 A1 · ¶ 15
and wherein each of the alkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, alkenyl and alkynyl groups in R, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R24, R25 and R30 are independently unsubstituted or substituted by 1 to 5 R32 groups independently selected from the group consisting of halo, alkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkylB · US 2009/0312341 A1 · ¶ 36
C1-6alkylcarbonyloxy; carboxyl; cyano; nitro; amino; mono- or di(C1-6alkyl)amino; polyhaloC1-6alkyl; polyhaloC1-6alkyloxy; polyhaloC1-6alkylthio;A · US 2006/0063789 A1 · ¶ 15
Especially preferred R groups in structure (1a) are alkyl, alkoxyalkyl and cycloalkylalkyl; especially preferred R14 groups in structure (1a) are hydrogen and alkyl, particularly wherein one R14 is hydrogen and the other is hydrogen or alkyl.B · US 2009/0312341 A1 · ¶
R5 and R6 each independently are hydrogen, R8, —Y1—NR9—Y2—NR10R11, —Y1—NR9—Y1—R8, —Y1—NR9R10, or R5 and R6 may together with the nitrogen to which they are attached form a saturated or partially saturated monocyclic 3 to 8 membered heterocycle or an aromatic 4 to 8 membered monocyclic heterocycle, each of said heterocycles may optionally be substituted with one or more substituents selected from R12, R13 and R14, or each of said heterocycles may optionally be fused with a benA · US 2006/0063789 A1 · ¶ 15
or R24 and R25 together with the nitrogen to which they are attached, form a 3-7 membered heterocycloalkyl ring;B · US 2009/0312341 A1 · ¶ 33
Y3 or Y4 each independently are a direct bond, C1-6alkanediyl, C2-6alkenediyl or C2-6alkynediyl; n is 1 or 2; m is 1 or 2; p is 1 or 2; r is 1 to 5; s is 1 to 3; aryl is phenyl or phenyl substituted with one, two, three, four or five substituents each independently selected from halo, C1-6alkyl, C3-7cycloalkyl, C1-6alkyloxy, cyano, nitro, polyhaloC1-6alkyl and polyhaloC1-6alkyloxy; provided that —X—R2 and/or R3 is other than hydrogen; and provided that the following compoundsA · US 2006/0063789 A1 · ¶ 15
In another embodiment, preferred are compounds of formula I, definition (A), wherein m is zero; n is 1 and the sum of n and l is 1 or 2;B · US 2009/0312341 A1 · ¶ 62
An empty cell means only that no passage was reproduced there.
The present invention concerns a novel group of compounds, their use as a medicine, their use for the manufacture of a medicament for the treatment of diseases mediated through glycogen synthase kinase 3, in particular glycogen synthase kinase 3β; processes for their preparation and pharmaceutical compositions comprising them.A · US 2006/0063789 A1 · ¶ 1
Therefore there is an unmet medical need for AD treatments that halt disease progression.B · US 2009/0312341 A1 · ¶ 3
Thus inhibition of BACE-1 is a therapeutic approach to the treatment of AD and other cognitive and neurodegenerative diseases caused by Aβ plaque deposition.B · US 2009/0312341 A1 · ¶ 7
patent.fyi, US 2026/0355189 A1, claim 1, first published 2026-11-19T09:07:06-05:00, https://patent.fyi/US20260355189/, SHA-256 b46a76b446fbdc2e7443c9df136d805c9e3f7cd912a7694c0ae5de7eb59d7570